Novo Nordisk and Orbis Medicines sign macrocycle discovery deal worth up to $1.4bn
Novo Nordisk and Orbis Medicines have entered a multi-target drug-discovery partnership worth up to $1.4 billion to develop orally bioavailable macrocycle medicines for cardiometabolic disease.
The collaboration will use Orbis' AI-enabled nGen platform to identify macrocyclic drug candidates against targets that have historically been difficult to address with conventional small molecules.
Orbis is eligible for upfront and milestone payments of up to $1.4 billion plus royalties, while Novo Nordisk will also make a strategic investment in the company.
Field | Content |
Alert Type | Deal |
Companies | Novo Nordisk; Orbis Medicines |
Deal Type | Multi-target drug discovery and licensing partnership |
Asset or Company | nGen macrocycle discovery platform |
Therapy Area(s) | Cardiometabolic disease |
Technology or Modality | Orally bioavailable macrocycles; AI-enabled drug discovery |
Deal Value | Up to US$1.4 billion in upfront and milestone payments, plus royalties and a strategic equity investment |
Geography | Global |
What Happened | Novo Nordisk and Orbis Medicines entered a multi-target partnership to discover and develop orally bioavailable macrocycle medicines for cardiometabolic diseases. |
Why It Matters | The deal gives Novo access to a platform designed to create oral medicines against targets that are difficult to address using conventional small-molecule approaches. |
Supporting Context | Orbis' nGen platform combines high-throughput macrocycle synthesis and artificial intelligence to identify orally bioavailable compounds with properties traditionally associated with larger biologic drugs. |
Strategic Rationale | Novo Nordisk gains access to a differentiated discovery technology while Orbis secures substantial development economics and validation of its macrocycle platform. |
Potential Impact | Successful programmes could expand the range of cardiometabolic targets that can be treated with convenient oral medicines. |
Key Takeaway | Novo Nordisk is committing up to US$1.4 billion to an Orbis Medicines macrocycle discovery partnership focused on cardiometabolic disease. |
What to Watch | Target selection, candidate nomination and progression of the first nGen-derived programmes into preclinical development. |
Primary Source | Orbis Medicines |
Relevant Date | 17 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments